Search Results
Your search for The ASCO Post matches 17144 pages
Showing 6551 - 6600Seattle Cancer Care Alliance Appoints Aaron Crane as Executive Vice President
Seattle Cancer Care Alliance (SCCA) has announced Aaron Crane as the new Executive Vice President. Mr. Crane will lead the organization’s strategic development, including its long-range financial plan and the upcoming clinic expansion at the South Lake Union campus. Since joining the organization...
Karen L. Reckamp, MD, MS, to Head Medical Oncology at Cedars-Sinai Cancer
Lung cancer expert Karen L. Reckamp, MD, MS, has been selected to be Director of the Division of Medical Oncology at Cedars-Sinai Cancer. Dr. Reckamp also will serve as Medical Oncology Director of the Women’s Guild Lung Institute in Cedars-Sinai’s Department of Medicine and Associate Director for ...
Denial’s Many Faces
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Doctoring in the Digital Age: Modern Stressors, Ancient Strategies to Cope
In my 45 years of practicing hematology/oncology at a major urban academic medical center, I have observed a sea change in daily practice that contributes to physician burnout. Although the emotional stresses of caring for seriously ill people play a part in physician burnout, I find the daily...
A Retired Oncologist Remains Involved in the Science and Policy of Oncology
The history of medicine once was featured in medical school curricula. That is becoming less common due to time restriction and the increased prevalence of more technical topics. However, the importance of the history of medicine cannot be overstated: It shapes every aspect of our cultural,...
Comparing Prescribing Habits in Academic and Nonacademic Oncology Settings
The art of oncology practice is tailored to the individual patient with cancer, and with the advent of highly personalized targeted therapies, patient outcomes have improved markedly over the past several decades. Although much of oncology practice is guideline- or protocol-driven, chemotherapy...
Incidence Increases in New Colorectal Cancer Diagnoses Among Patients Between 49 and 50 Years Old
A year-by-year age analysis of colorectal cancer rates among adults in the United States has found a 46% increase in new diagnoses from ages 49 to 50, indicating that many latent cases of the disease are likely going undiagnosed until routine screenings begin at 50, according to a new study by...
Is Distance to Treatment a Burden for Rural Patients With Breast Cancer?
A study published by Longacre et al in The Journal of Rural Health found that patients with breast cancer in the rural United States typically travel three times farther than those who live in urban areas for radiation therapy. Researchers examined data from the Surveillance, Epidemiology, and End ...
Circulating Tumor Cell Assessment to Predict Melanoma Relapse
A study published by Anthony Lucci, MD, and colleagues in Clinical Cancer Research showed that the presence of circulating tumor cells was independently associated with relapse of melanoma, suggesting circulating tumor cell assessment may be a useful tool for identifying patients at risk for...
Diffusion-Weighted MRI May Help Predict Treatment Response in Patients With Advanced Ovarian Cancer
A simple test using a magnetic resonance imaging (MRI) scan may be used to predict how well people with advanced epithelial ovarian cancer will respond to treatment, according to the results of a new study published by Winfield et al in Radiology. In a large clinical trial, scientists have shown a...
WHO, IARC Release Reports in Response to Government’s Role in Cancer Control
The World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) released two coordinated reports in light of World Cancer Day in response to government calls for more research into the scope and potential policies and programs to improve cancer control. WHO Report...
World Cancer Day 2020: 20th Anniversary of the Global Initiative
Today’s World Cancer Day, led by the Union for International Cancer Control (UICC), aims to mobilize urgent action from individuals, governments, and the global cancer community to close gaps in cancer risk awareness between higher and lower socioeconomic groups and the subsequent impact on their...
CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas: Present and Future
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel immunotherapies for patients with different types of non-Hodgkin...
AMA Foundation Launches New Initiative to Address LGBTQ Health Disparities
The American Medical Association Foundation (AMAF) recently announced a new initiative to create a cadre of LGBTQ health specialists through the AMA Foundation LGBTQ Fellowship Program—a national fellowship program to promote best practices and shared outcomes, while improving the quality of LGBTQ ...
Expert Point of View: Harold J. Burstein, MD, PhD, FASCO
Commenting on Dr. DeMichele’s poster presentation at the 2019 San Antonio Breast Cancer Symposium, Harold J. Burstein, MD, PhD, FASCO, Professor of Medicine at Harvard Medical School and a medical oncologist at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, told The ASCO...
Real-World Use of Palbociclib and Abemaciclib Explored in Two Studies Based on Electronic Health Records Database
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are changing the landscape of the treatment of hormone receptor (HR)-positive/HER2-negative breast cancer. Three CDK4/6 inhibitors are approved by the U.S. Food and Drug Administration—ribociclib, palbociclib, and abemaciclib—as first- or...
ASCO’s Inaugural Breakthrough Global Summit Showcased Evolving Technologies Poised to Revolutionize Cancer Care
Unlike ASCO’s Annual Meeting, symposia, and conferences, which highlight the current scientific advances in specific cancers and how they are improving cancer outcomes for the more than 18.1 million people worldwide diagnosed with cancer each year,1 ASCO Breakthrough: A Global Summit for Oncology...
Patient Aid Improved Lung Cancer Screening Informed Decision-Making
In the first comparative clinical trial of lung cancer screening decision aid vs standard educational information, researchers from The University of Texas MD Anderson Cancer Center showed that a decision aid delivered through tobacco quitlines effectively reaches a screening-eligible population...
FDA Pipeline: Priority Review Granted for Treatment in Lung and Thyroid Cancers
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to a treatment for lung and thyroid cancers with a RET fusion or mutation; gave Breakthrough Therapy designation to a doublet therapy for TP53-mutated myelodysplastic syndromes; and issued an update to their...
Equal-Access Health-Care System for African American and White Men With Prostate Cancer
Among men with prostate cancer who received care from the U.S. Department of Veterans Affairs (VA) Health System, an equal-access health-care system, African American men did not have more advanced disease at the time of diagnosis or die earlier than white men, unlike trends seen in the greater...
Gabapentin and Methadone for Patients Undergoing Treatment of Head and Neck Cancer
With nearly all patients who undergo treatment for cancer of the head and neck experiencing oral mucositis, effective pain control is one of the main goals of physicians and care teams. Looking to provide more effective relief for patients—while also reducing the need for opioid painkillers—a team...
Thomas Yau, MBBS, on Advanced Hepatocellular Carcinoma: CheckMate 040 Trial of Nivolumab, Ipilimumab, and Cabozantinib
Thomas Yau, MBBS, of the University of Hong Kong, discusses this triplet combination, which yielded better responses than doublet combination therapy in patients with advanced liver cancer, but with more severe adverse events and more treatment discontinuations (Abstract 478).
Brian M. Wolpin, MD, on Performance of a Blood-Based Test for the Detection of Multiple Cancers
Brian M. Wolpin, MD, of Dana-Farber Cancer Institute, discusses a noninvasive blood test evaluating methylation of circulating free DNA. In his study, the blood test detected multiple gastrointestinal cancers at a sensitivity of approximately 81% and a prespecified specificity of > 99%. It also...
Expert Point of View: Basem M. William, MD, MRCP(UK), FACP
Basem M. William, MD, MRCP(UK), FACP, Director of the T-Cell Lymphoma Program and Member of the Blood and Marrow Transplant Program at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, commented on the...
STS 2020: Intraoperative Molecular Imaging Technology Helps Surgeons to Detect NSCLC
A tumor-highlighting technology—OTL38—enhances the visualization of lung cancer tissue, providing surgeons with a significantly better chance of finding and removing more cancer than previously possible, according to a scientific presentation by Gangadharan et al at the Plenary Session of the 56th...
Late-Stage Cancer Diagnoses After Massachusetts Health Insurance Reform Law
Advanced-stage cancer diagnoses declined following health insurance expansion in Massachusetts, likely due to increased access to screening and diagnostic services that identified cancers earlier, according to new research published by Sabik et al in the journal Medical Care. The analysis...
Ringing a Bell on the Last Day of Radiation Therapy: Helpful or Harmful?
Some patients with cancer celebrate the end of a course of radiation or chemotherapy by ringing a bell. Indeed, many patients say they love the graduation-like ceremony and the sense of closure it gives them. However, a study published by Williams et al in the International Journal of Radiation...
Danielle S. Bitterman, MD, on Pancreatic Cancer: Noninvasive Genomic Profiling From Plasma ctDNA
Danielle S. Bitterman, MD, of the Harvard University Radiation Oncology Program and Massachusetts General Hospital, discusses an analysis of genomic and clinical data from 97 patients with pancreatic ductal adenocarcinoma with circulating tumor DNA. Mutations were most frequently detected in...
Thibaud Kössler, MD, PhD, on Localized Rectal Cancer: Neoadjuvant Pembrolizumab and Radiotherapy
Thibaud Kössler, MD, PhD, of Geneva University Hospital, discusses the first trial to study the efficacy and safety of anti–PD-1 immunotherapy plus short-course radiotherapy in localized microsatellite-stable rectal cancer. The study explores whether a gene signature can predict sensitivity to...
Eyal Meiri, MD, on Pembrolizumab in Colorectal Cancer: Results From the TAPUR Study
Eyal Meiri, MD, of the Cancer Treatment Centers of America at Southeastern Regional Medical Center, discusses his findings on heavily pretreated patients with colorectal cancer with high tumor mutational burden. Monotherapy with pembrolizumab showed antitumor activity, which merits further study to ...
Franck Pagès, MD, PhD, on Stage III Colon Cancer: IDEA Study on a Risk Assessment Tool
Franck Pagès, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses study findings from the prospective IDEA France cohort study of patients with stage III colon cancer treated with mFOLFOX6. The study showed that patients with an intermediate or high Immunoscore seemed to benefit from 6...
Van K. Morris, MD, on Stage II Colon Cancer: Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy
Van K. Morris, MD, of The University of Texas MD Anderson Cancer Center, discusses the COBRA study, which is examining circulating tumor DNA and its ability to predict whether patients with resected stage IIA colon cancer may benefit from adjuvant chemotherapy (Abstract TPS261).
Peter R. Galle, MD, on Atezolizumab/Bevacizumab vs Sorafenib for Hepatocellular Carcinoma: Patient-Reported Outcomes
Peter R. Galle, MD, of the University Medical Center, Mainz, discusses patient-reported outcomes from this phase III study, which showed the combination of atezolizumab plus bevacizumab vs sorafenib is well tolerated and may represent a new standard of care in the first-line setting for...
Zev A. Wainberg, MD, on PD-L1–Positive Advanced Gastric Cancer: MSI and Combined Positive Score and Pembrolizumab vs Chemotherapy
Zev A. Wainberg, MD, of the UCLA Medical Center, discusses the first subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in PD-L1–positive disease (Abstract 427).
Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy
Heinz-Josef Lenz, MD, of USC Norris Comprehensive Cancer Center, discusses how treating microsatellite instability–high/DNA mismatch repair–deficient metastatic colorectal cancer with nivolumab once every 2 weeks plus low-dose ipilimumab every 6 weeks may represent a new option for patients...
‘Unprecedented’ Responses to Cisplatin/Gemcitabine in BRCA-Mutated Advanced Pancreatic Cancer
As first-line treatment of patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation, cisplatin plus gemcitabine yielded high response rates and encouraging survival, establishing this doublet as a standard approach in this subset of patients, according to Eileen M....
Few Patients Enroll in Clinical Trials of First-Line Therapies
Patient enrollment in clinical trials as the first course of treatment after cancer diagnosis is low, despite the fact that enrollment may increase life expectancy, according to research published by Zaorsky et al in JNCCN–Journal of the National Comprehensive Cancer Network. Researchers also found ...
Obstacles to Early Detection of Skin Cancer in Patients Living in Rural Western States
Residents of rural, sparsely populated “frontier counties” in the western United States have a higher incidence of skin cancer and related mortality rates. New research published by Jensen et al in Psychology, Health & Medicine indicated that the biggest obstacle to early detection and...
CMS Expands Coverage of Next-Generation Sequencing for Patients With Breast or Ovarian Cancer
On January 27, the Centers for Medicare & Medicaid Services (CMS) took action to cover U.S. Food and Drug Administration–approved or –cleared laboratory diagnostic tests using next-generation sequencing (NGS) for patients with germline ovarian or breast cancer. Over the last several years, CMS ...
Scott Kopetz, MD, PhD, on Metastatic Colorectal Cancer: Quality of Life Results on Encorafenib, Cetuximab, and Binimetinib
Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the BEACON CRC trial, which had demonstrated that the triplet regimen of encorafenib, cetuximab, and binimetinib significantly improved overall survival in patients with a BRAF V600E...
Eileen M. O’Reilly, MD, on Pancreatic Adenocarcinoma: Gemcitabine, Cisplatin, and Veliparib
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II trial findings showing that cisplatin and gemcitabine, with or without veliparib, exceeded a prespecified response rate for patients with pancreatic adenocarcinoma and a germline BRCA/PALB2 mutation (Abstract 639).
FDA Pipeline: Priority Reviews in Multiple Myeloma, Prostate Cancer
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for multiple myeloma and prostate cancer; gave Fast Track designation to a targeted gene therapy for lung cancer; granted Orphan Drug designation to a combination therapy for hepatocellular...
2020 GI Cancers Symposium: Cost of Pancreatic Cancer Care Over Time
In a study presented by Picozzi et al at the 2020 Gastrointestinal Cancers Symposium, researchers found that even as drug costs increased over the past decade, total inflation-adjusted pancreatic cancer care expenses declined, as did costs related to quality of life (Abstract 773). Health...
Surgeon General Releases Report Focused on Smoking Cessation
Three decades after the first Surgeon General's report on smoking cessation, the Surgeon General has released a new report that reviews and updates evidence on the importance of quitting smoking. The report finds that more than two-thirds of U.S. adult cigarette smokers report an interest in...
FDA Approves Tazemetostat for Epithelioid Sarcoma
On January 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. “Epithelioid sarcoma accounts...
Yale Cancer Center Launches Center for Community Engagement and Health Equity
Yale Cancer Center has announced the launch of the Center for Community Engagement and Health Equity (CEHE). Building on the commitment of the Yale Cancer Center to patient-centered cancer care, screening, and prevention across the state of Connecticut, the new center is dedicated to ensuring...
Expert Point of View: Virginia Kaklamani, MD, Steven Vogl, MD, Gary Lyman, MD, MPH, and Ginny Mason, BSN
For several breast cancer experts interviewed by The ASCO Post, the phase III oral paclitaxel study and the drug itself had some limitations. Virginia Kaklamani, MD, of UT Health San Antonio, moderator of a press briefing, thought that the dosing process and the 11 pills or so per day was a...
Elizabeth Fox, MD, Named Senior Vice President of Clinical Trials Research at St. Jude
St. Jude Children’s Research Hospital announced recently that Elizabeth Fox, MD, has been named Senior Vice President of Clinical Trials Research. In this role, Dr. Fox will oversee clinical trials research administration and strategy at St. Jude. She will also serve as Associate Director for...
Dolores Hambardzumyan, PhD, MBA, Joins Neurosurgery Faculty at Mount Sinai
Dolores Hambardzumyan, PhD, MBA, has been appointed Senior Faculty in the Department of Neurosurgery and a member of The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Her research focuses on developing novel therapeutic pathways for the treatment of glioblastoma. She is...
Kunle Odunsi, MD, PhD, FRCOG, FACOG, Elected to Lead AACR Immunology Working Group
Chosen for his passion and leadership in immunotherapy research, Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, was elected as the Cancer Immunology Working Group (CIMM) Chairperson-Elect for 2020–2021. CIMM is a scientific working group within the...
